Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors.

Gessa GL, Melis M, Muntoni AL, Diana M.

Eur J Pharmacol. 1998 Jan 2;341(1):39-44.

PMID:
9489854
3.

Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal.

Rodríguez de Fonseca F, Carrera MR, Navarro M, Koob GF, Weiss F.

Science. 1997 Jun 27;276(5321):2050-4.

5.

Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra.

French ED, Dillon K, Wu X.

Neuroreport. 1997 Feb 10;8(3):649-52.

PMID:
9106740
6.

Mesolimbic dopaminergic reduction outlasts ethanol withdrawal syndrome: evidence of protracted abstinence.

Diana M, Pistis M, Muntoni A, Gessa G.

Neuroscience. 1996 Mar;71(2):411-5.

PMID:
9053796
7.

Chronic morphine induces visible changes in the morphology of mesolimbic dopamine neurons.

Sklair-Tavron L, Shi WX, Lane SB, Harris HW, Bunney BS, Nestler EJ.

Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11202-7.

8.

Synaptic regulation of mesocorticolimbic dopamine neurons.

White FJ.

Annu Rev Neurosci. 1996;19:405-36. Review.

PMID:
8833449
9.

Drug addiction: the yin and yang of hedonic homeostasis.

Koob GF.

Neuron. 1996 May;16(5):893-6. Review. No abstract available.

10.
11.
12.

Drug addiction: a model for the molecular basis of neural plasticity.

Nestler EJ, Hope BT, Widnell KL.

Neuron. 1993 Dec;11(6):995-1006. Review. No abstract available.

PMID:
8274284
13.

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.

Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, et al.

FEBS Lett. 1994 Aug 22;350(2-3):240-4.

14.

Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome.

Harris GC, Aston-Jones G.

Nature. 1994 Sep 8;371(6493):155-7.

PMID:
7915401
15.

Profound decrease of mesolimbic dopaminergic neuronal activity in morphine withdrawn rats.

Diana M, Pistis M, Muntoni A, Gessa G.

J Pharmacol Exp Ther. 1995 Feb;272(2):781-5.

PMID:
7853194
16.

Molecular mechanisms of drug reinforcement and addiction.

Self DW, Nestler EJ.

Annu Rev Neurosci. 1995;18:463-95. Review. No abstract available.

PMID:
7605071
17.
18.

Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.

Aceto MD, Scates SM, Lowe JA, Martin BR.

Eur J Pharmacol. 1995 Aug 25;282(1-3):R1-2.

PMID:
7498260
19.

Antidromic activation of neurones as an analytic tool in the study of the central nervous system.

Lipski J.

J Neurosci Methods. 1981 Jun;4(1):1-32. No abstract available.

PMID:
7253697
20.

Supplemental Content

Support Center